Document is current
Any future updates will be listed below
-
Authors
Ofori-Anyinam, Boatema
Hamblin, Meagan
Coldren, Miranda L.
Li, Barry https://orcid.org/0000-0003-1102-561X
Mereddy, Gautam
Shaikh, Mustafa
Shah, Avi
Grady, Courtney
Ranu, Navpreet
Lu, Sean
Blainey, Paul C. https://orcid.org/0000-0002-4889-8783
Ma, Shuyi https://orcid.org/0000-0003-0783-1328
Collins, James J. https://orcid.org/0000-0002-5560-8246
Yang, Jason H. https://orcid.org/0000-0003-0921-4657
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R00-GM118907, U19-AI62589, R21-AI121932, RM1-HG006193, U19-AI62598, R01-AI146194, U19-AI11276)
NSF | NSF Office of the Director | Office of International Science and Engineering
Burroughs Wellcome Fund
United States Department of Defense | Defense Threat Reduction Agency (HDTRA12210032)
Anita and Josh Bekenstein
- License Information
-
More Information
Article History
Received: 1 January 2024
Accepted: 28 October 2024
First Online: 13 November 2024
Competing interests
: J.J.C. is a co-founder and board member of Phare Bio, a nonprofit venture focused on antibiotic drug development. P.C.B. is a consultant to or holds equity in 10X Genomics, General Automation Lab Technologies/Isolation Bio, Celsius Therapeutics, Next Gen Diagnostics, Cache DNA, Concerto Biosciences, Stately Bio, Ramona Optics, Bifrost Biosystems, and Amber Bio. His laboratory has received research funding from Calico Life Sciences, Merck, and Genentech for unrelated work. None of these interests are connected to this study. The remaining authors declare no competing interests.
